logo-loader
viewRPC Group

Apollo Global Management said to be nearing deal to buy RPC for over US$3.8bn

A deal could be announced as soon as Tuesday, according to the Wall Street Journal

RPC
There are concerns a clampdown on plastic waste could hurt demand for RPC

Private equity firm Apollo Global Management is reportedly nearing a deal to buy packaging company RPC Group PLC for more than US$3.8bn after extending the deadline for a takeover offer several times.

A deal could be announced as soon as Tuesday, according to the Wall Street Journal.

On Friday, RPC said the UK’s takeover panel had granted another extension on the deadline Apollo needs to make a firm offer for the company. Apollo must make an offer by no later than 5 pm on January 23.

RPC repeated that discussions with Apollo were at an advanced stage with due diligence complete.

READ: D-day for Apollo Global Management to 'put up or shut up' with offer for RPC

The deal deadline has been extended each month since RPC announced it was in talks with Apollo in September.

For Apollo, a 22% decline in RPC shares last year presents a buying opportunity if it can address the firm’s challenges such as an EU and UK clampdown on plastic waste.

Apollo is under pressure the invest the cash it has raised after pulling out of some auctions for major acquisitions including for the speciality chemicals business of Dutch paints maker Akzo Nobel NV. 

Quick facts: RPC Group

Price: - -

LSE:RPC
Market: LSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: Analysis of data from AEGIS-H2H is strongly supportive...

Proactive Research analyst Emma Ulker says further conclusions from Shield Therapeutics' (LON:STX) analysis of data from the AEGIS-H2H study are strongly supportive of ongoing discussions for the global commercialisation, pricing and reimbursement of Feraccru. She adds that with the analysis...

13 minutes ago

2 min read